The U.S. Food and Drug Administration (FDA) has approved an expanded indication for HAEGARDA for routine prophylaxis to prevent HAE attacks in patients 6 years of age and older. HAEGARDA, the HAE therapy that reduces attacks by a median of 95%, is now the first and only subcutaneous treatment option for prevention of HAE attacks … Continue reading FDA Approves HAEGARDA for Prevention of HAE Attacks in Pediatric Patients